Navigation Links
Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
Date:5/6/2013

domized Phase 3 trial will evaluate MEK162 against physician's choice of standard chemotherapy treatments in 300 patients with recurrent or persistent LGSOC following at least one prior platinum-based chemotherapy regimen and no more than three lines of prior chemotherapy regimens. The primary endpoint is progression-free survival, and the key secondary endpoint is overall survival.

"This trial is yet another indication of our continued progress towards our products being commercialized," said Ron Squarer, Chief Executive Officer, Array BioPharma.  "MEK162 is planned to be in three pivotal trials, which along with other ongoing and planned studies, is expected to position this drug to demonstrate its broad activity across a variety of tumor types."

As part of the agreement with Novartis, Array is entitled to royalties on worldwide sales, with royalties on U.S. sales at a higher level. Array is co-developing MEK162 with Novartis and retains an option to co-detail the product in the United States.

About Low-grade Serous Ovarian Cancer
Ovarian cancer is the tenth most common cancer among women, the fifth leading cause of cancer-related death among women, and is the deadliest of gynecologic cancers.  Serous ovarian cancer represents the largest group of ovarian cancer and is considered to consist of two main subtypes: low-grade and high-grade.  LGSOC represents up to 10 percent of ovarian cancer diagnoses, and it is estimated that over 10,000 women are living with the disease in the United States and Europe.  Patients with LGSOC are generally diagnosed at a younger age and live longer, but have a lower response rate to conventional chemotherapy compared to patients with high-grade serous ovarian cancer.  Management for advanced disease involves surgery and multiple anti-cancer regimens.  Less than 4 percent of patients with recurrent LGSOC respond to chemotherapy
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Kinex Pharmaceuticals announced the receipt of ... KX2-391 Ointment for the commencement of a Phase I ... third IND to be allowed by the US FDA ... a synthetic, orally active and highly selective inhibitor of ... the induction of p53, G2/M arrest of proliferating cell ...
(Date:7/24/2014)... 2014 Consolidated Net Profit increased by 43.65 ...   , India Business grew by 20.87% to Rs. ... 4,886.70 Mn Rest of World (ROW) Business grew by ... by 34.53% to Rs. 977.26 Mn Latin America Business ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today ...
(Date:7/24/2014)... 2014 Boston Children,s Hospital,s Global Pediatric Summit ... feature an "Innovation Tank" – a forum designed to ... their business or product solution to a panel of ... how to accelerate the innovation and bring it to ... Friday, October 31, will be moderated by Daymond ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... July 12, 2011 Vapotherm, a privately held manufacturer of ... that it has signed a new exclusive distribution agreement with ... Korea for the Vapotherm acute care product line. ... Hippo to bring high flow therapy to the Korean market," ...
... 12, 2011 UBM TechInsights, the leader in technical ... announced today that medical devices industry veteran Bill Betten ... Devices.  In this role Mr. Betten will draw upon ... medical device sector maximize the effectiveness of the product ...
Cached Medicine Technology:Vapotherm Announces New Exclusive Distribution Agreement with Hippo Medical for South Korea 2UBM TechInsights Hires Medical Devices Industry Veteran Bill Betten 2
(Date:7/25/2014)... Tampa, FL (PRWEB) July 25, 2014 ... launches their innovative toothbrushes with antibacterial silver that naturally kill ... land on the brush. , A toothbrush is the ... diseases, dental health and hygiene, however, it is subject to ... the air. , There are more bacteria in the mouth ...
(Date:7/24/2014)... 2014 Dr. Henry H. Ting, a ... has been appointed senior vice president and chief quality ... his new role, he will oversee the hospital's clinical ... successfully led quality initiatives and interprofessional teams at the ... for the Door-to-Balloon Alliance, a collaboration of more than ...
(Date:7/24/2014)... to light at night, which shuts off nighttime production ... to tamoxifen, a widely used breast cancer drug, says ... cancer researchers. The study, "Circadian and Melatonin Disruption by ... Tamoxifen Therapy in Breast Cancer," published in the journal ... that melatonin is vital to the success of tamoxifen ...
(Date:7/24/2014)... Park, NC (PRWEB) July 24, 2014 ... ethnic minorities, and low-income households are disproportionately affected ... public food safety net in the United States, ... , Under Section 743 of the Consolidated Appropriations ... Department of Agriculture's Food and Nutrition Service (FNS) ...
(Date:7/24/2014)... Monica, CA (PRWEB) July 24, 2014 ... health seriously, they must consider their own financial and ... flabby and weak marketing campaigns to the next level ... CallFire’s Cloud Call Center, IVR, Voice Broadcast, Call Tracking ... than a 98% open rate, text messages are quickly ...
Breaking Medicine News(10 mins):Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 2Health News:Silver®Care’s New Silver Antibacterial Toothbrushes Naturally Kill Oral Germs 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Total darkness at night is key to success of breast cancer therapy -- Tulane study 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 2Health News:Report: Vulnerable Populations Disproportionately Affected by Food Security, Despite Public Programs 3Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3
... that a new strain of E. coli O157was responsible for ... in Europe and Australia, but is apparently very rare in ... the laboratory from other types of E.coli O157 and this ... it,' said HPS consultant Dr John Cowden. 'It produces the ...
... In a bid to save its plummeting sales of chicken ... //The campaign would ensure that the customers get ... been planned by McDonald’s Corp., of Oakbrook, Ill. , ... ensure that is a epidemic and bird flu scare spread ...
... study that was published in Urology Journal BJUI International has ... and almost half of 19-year-olds who have a problem are ... the Chinese University of Hong Kong and the Prince of ... questionnaires surveying children who were aged 5 to 19. The ...
... popular drug for depression has been studied by researchers, in ... from the Cold Spring Harbor Laboratory// in Long Island, New ... immature brain cells. ,This could pave the way ... Alzheimer's. The researchers, as part of their study, analyzed proteins ...
... 2007, cigarette packets will carry graphic representations depicting the dangerous ... ward off the smoking habit. The pictorial representation could be ... womb. ,A website installed by the Department of Health, ... range of pictures that intend to underline the pitfalls of ...
... is a private company and was set up in 1994 in ... accepted to provide health care facility// free of cost to NHS ... General Practitioners for 7,000 patients and employ 3 doctors and 7 ... in London. ,The deal has been signed by ...
Cached Medicine News:
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad ... in a wide variety of ophthalmic ... packaged sterile, complete with a safety ... "off " position when not in ...
... The Luminary LASIK Light Probes provide ... that allows the corneal interface to be ... use of the Tindal effect and light ... of interface debris, epithelial deposits, flap edge ...
... EEG system designed to satisfy the needs ... center. Ready to use, Comet XL is ... and Photic Stimulator. Select from various mobile ... your individual needs. These powerful, easy-to-use EEG ...
Medicine Products: